Ramucirumab + Somatostatin Analog for Carcinoid Tumor
Trial Summary
What is the purpose of this trial?
This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
Research Team
Jennifer A Chan, MD MPH
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
Adults with advanced, progressive carcinoid tumors (excluding pancreatic neuroendocrine tumors) who have shown disease progression in the last year. Participants must have measurable disease, stable organ and marrow function, no major surgery or chemotherapy within 4 weeks prior to enrollment, and not be on certain medications like chronic antiplatelet therapy. Pregnant or breastfeeding women are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Ramucirumab in combination with Somatostatin Analog every 14 days in a 28-day cycle
Follow-up
Participants are monitored for progression-free survival and overall survival
Treatment Details
Interventions
- Ramucirumab
- Somatostatin Analog
Ramucirumab is already approved in United States, European Union, Japan for the following indications:
- Gastric cancer
- Non-small cell lung cancer
- Colorectal cancer
- Hepatocellular carcinoma
- Gastric cancer
- Non-small cell lung cancer
- Colorectal cancer
- Gastric cancer
- Non-small cell lung cancer
- Colorectal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Eli Lilly and Company
Industry Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University